التفاصيل البيبلوغرافية
| العنوان: |
Long-term deprescription in chronic pain and opioid use disorder patients: Pharmacogenetic and sex differences |
| المؤلفون: |
Muriel Javier, Escorial Mónica, Margarit César, Barrachina Jordi, Carvajal Cristian, Morales Domingo, Peiró Ana M. |
| المصدر: |
Acta Pharmaceutica, Vol 73, Iss 2, Pp 227-241 (2023) |
| بيانات النشر: |
Sciendo, 2023. |
| سنة النشر: |
2023 |
| المجموعة: |
LCC:Pharmaceutical industry |
| مصطلحات موضوعية: |
chronic pain, drug deprescription, opioid use disorder, long-term monitoring, pharmacogenetics, sex differences, Pharmaceutical industry, HD9665-9675 |
| الوصف: |
More than half of patients with opioid use disorder for chronic non-cancer pain (CNCP) reduced their dose through a progressive opioid withdrawal supported by a rotation to buprenorphine and/or tramadol. The aim of this research is to analyse the long-term effectiveness of opioid deprescription taking into account the impact of sex and pharmacogenetics on the inter-individual variability. A cross-sectional study was carried out from October 2019 to June 2020 on CNCP patients who had previously undergone an opioid deprescription (n = 119 patients). Demographic, clinical (pain, relief and adverse events) and therapeutic (analgesic use) outcomes were collected. Effectiveness (< 50 mg per day of morphine equivalent daily dose without any aberrant opioid use behaviour) and safety (number of side-effects) were analysed in relation to sex differences and pharmacogenetic markers impact [OPRM1 genotype (rs1799971) and CYP2D6 phenotypes]. Long-term opioid deprescription was achieved in 49 % of the patients with an increase in pain relief and a reduction of adverse events. CYP2D6 poor metabolizers showed the lowest long-term opioid doses. Here, women showed a higher degree of opioid deprescription, but increased use of tramadol and neuromodulators, as well as an increased number of adverse events. Long-term deprescription was successful in half of the cases. Understanding sex and gender interaction plus a genetic impact could help to design more individualized strategies for opioid deprescription. |
| نوع الوثيقة: |
article |
| وصف الملف: |
electronic resource |
| اللغة: |
English |
| تدمد: |
1846-9558 |
| Relation: |
https://doaj.org/toc/1846-9558 |
| DOI: |
10.2478/acph-2023-0018 |
| URL الوصول: |
https://doaj.org/article/ed5d0f056c014a5b95621f8fb4acd9cf |
| رقم الانضمام: |
edsdoj.5d0f056c014a5b95621f8fb4acd9cf |
| قاعدة البيانات: |
Directory of Open Access Journals |
Full Text Finder